BRTX Biorestorative Therapies
- 1.490
- +0.060+4.20%
- 1.490
- 0.0000.00%
Biorestorative Therapies News
Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Maintains Target Price $6
Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Maintains Target Price $6
Positive Outlook for BioRestorative Therapies: Phase 2 Trial Results Drive Buy Rating
Roth MKM Remains a Buy on BioRestorative Therapies (BRTX)
Roth MKM Reaffirms Their Buy Rating on BioRestorative Therapies (BRTX)
Maxim Group Maintains Biorestorative Therapies(BRTX.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed for BioRestorative Therapies Amid Strong Financials and Clinical Progress
BioRestorative Therapies Analyst Ratings
Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18
BioRestorative Therapies Analyst Ratings
Strong Buy Rating for BioRestorative Therapies Amidst Strategic Partnerships and Innovative Clinical Progress
Buy Rating on BioRestorative Therapies for Innovative Obesity Treatment Approach
Buy Rating on BioRestorative Therapies: Innovative Cell-based Therapies and Strategic Growth Opportunities
Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and BioRestorative Therapies (BRTX)
Promising Early Phase 2 Results for BioRestorative Therapies' BRTX-100 Lead to Buy Rating
Roth MKM Reiterates Buy on BioRestorative Therapies, Maintains $15 Price Target
BioRestorative Therapies Analyst Ratings
Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), BioRestorative Therapies (BRTX)
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and BioRestorative Therapies (BRTX)
BioRestorative Therapies (BRTX) Gets a Buy From Maxim Group
No Data